São Paulo - Delayed Quote BRL

Pfizer Inc. (PFIZ34.SA)

32.44

+0.64

+(2.01%)

As of 1:59:56 PM GMT-3. Market Open.

Why vaccine makers aren't worried about Trump administration cuts

Vaccines have been a central focus for Trump's health leaders, but large-cap players aren't feeling the sting.

Yahoo Finance 22 hours ago

MRNA

MRK

SNY
PFE vs. LLY: Which Stock Should Value Investors Buy Now?

PFE vs. LLY: Which Stock Is the Better Value Option?

Zacks 1 hour ago

LLY

PFE
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 3 hours ago

LLY

PFE
Are Investors Undervaluing Pfizer (PFE) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 3 hours ago

PFE
Curious about Pfizer (PFE) Q1 Performance? Explore Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Pfizer (PFE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.

Zacks 4 hours ago

PFE
With 67% institutional ownership, Pfizer Inc. (NYSE:PFE) is a favorite amongst the big guns

Key Insights Institutions' substantial holdings in Pfizer implies that they have significant influence over the...

Simply Wall St. 4 hours ago

PFE
Stocks That Pay Almost 10% Dividend Yields: Dow and Lyondell

Chemicals firms Dow and LyondellBasell are the biggest dividend payers in the S&P 500. Other fat divided payouts include Pfizer, Franklin Resources, and Invesco.

Barrons.com 4 hours ago

LYB

PFE

MO
Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth

SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025.

Zacks 5 hours ago

SNY

PFE
2 No-Brainer Stocks to Buy With Less Than $30

Having significant capital in the bank when investing in equities is helpful, but is by no means necessary. If you're patient and hold on to it through the kind of market volatility we're experiencing, while occasionally purchasing more shares, that should result in excellent returns. Let's consider two great options: Pfizer (NYSE: PFE) and Adyen (OTC: ADYE.Y).

Motley Fool 6 hours ago

PFE
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

In the closing of the recent trading day, Pfizer (PFE) stood at $22.36, denoting a -0.78% change from the preceding trading day.

Zacks 19 hours ago

PFE
Pfizer Declares Second-Quarter 2025 Dividend

NEW YORK, April 23, 2025--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company’s common stock, payable June 13, 2025, to holders of the Common Stock of record at the close of business on May 9, 2025. The second-quarter 2025 cash dividend will be the 346th consecutive quarterly dividend paid by Pfizer.

Business Wire 20 hours ago

PFE
Why Is Summit Therapeutics Stock Soaring On Wednesday?

Summit Therapeutics Inc.'s (NASDAQ:SMMT) partner, Akeso, Inc., released topline data from the Phase 3 HARMONi-6/K112-306 trial on Wednesday. The trial is evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, an anti-PD-1 antibody, in combination with platinum-based chemotherapy in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. HARMONi-6 is a study conducted in China sponsored

Benzinga 21 hours ago

SMMT

AKESF

PFE
Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting

NEW YORK, April 23, 2025--Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 30 to June 3 in Chicago. Data from more than 60 company-sponsored, investigator-sponsored, and collaborative research abstracts, including 9 oral presentations and 6 rapid oral presentations, will be presented across Pfizer’s key tumor areas, including breast, genitourinary,

Business Wire 21 hours ago

PFE
3 of Wall Street’s Favorite Stocks Walking a Fine Line

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

StockStory yesterday

PFE

MTN

INSE
2 High-Yield Dividend Stocks to Buy for Passive Income

Passive income is essential in retirement, but building a dependable stream isn't easy. Fortunately, top-tier dividend stocks can do the heavy lifting. In today's volatile market, where uncertainty is the only constant, dividend investing has regained its shine.

Motley Fool yesterday

PFE

ABBV
Pfizer Stock Before Q1 Earnings Release: To Buy or Not to Buy?

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.

Zacks yesterday

PFE
What's Next for Pfizer After the Company Pulls Its Weight Loss Drug?

The anti-obesity drug market has the potential to be massive, with multiple analysts projecting it may reach at least $100 billion by 2030. As a result, many top healthcare companies are vying for a piece of the market, as doing so could generate significant revenue and profit growth. Pfizer (NYSE: PFE) has been one of those companies, with danuglipron being a treatment it was hopeful could eventually come to market as a once-daily pill.

Motley Fool yesterday

PFE
S&P 500 Sell-Off: 2 Ultra-High-Yield Dividend Stocks That Make for No-Brainer Buys

Two brand-name, time-tested companies -- sporting an average yield of 7% -- are ripe for the picking amid a historic bout of volatility on Wall Street.

Motley Fool yesterday

^GSPC

F

PFE
Novo Nordisk Pops After Leapfrogging Eli Lilly With An Obesity Pill

Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.

Investor's Business Daily yesterday

PFE

LLY

NONOF
Jim Cramer Warns on Pfizer (PFE): “That 7.7% Yield Is Not a Sign of Strength – It’s a Sign of Weakness”

We recently published a list of Jim Cramer’s Thoughts on These 5 Stocks. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discussed. On Thursday’s episode of Mad Money, Jim Cramer addressed the growing friction between Federal Reserve Chairman Jerome Powell and […]

Insider Monkey yesterday

PFE

Performance Overview

Return	PFIZ34.SA	S&P 500 (^GSPC)
YTD	-19.91%	-6.99%
1-Year	-0.72%	+7.86%
3-Year	-36.61%	+28.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Pfizer Inc. (PFIZ34.SA)

Why vaccine makers aren't worried about Trump administration cuts

PFE vs. LLY: Which Stock Should Value Investors Buy Now?

Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Are Investors Undervaluing Pfizer (PFE) Right Now?

Curious about Pfizer (PFE) Q1 Performance? Explore Wall Street Estimates for Key Metrics

With 67% institutional ownership, Pfizer Inc. (NYSE:PFE) is a favorite amongst the big guns

Stocks That Pay Almost 10% Dividend Yields: Dow and Lyondell

Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth

2 No-Brainer Stocks to Buy With Less Than $30

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

Pfizer Declares Second-Quarter 2025 Dividend

Why Is Summit Therapeutics Stock Soaring On Wednesday?

Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting

3 of Wall Street’s Favorite Stocks Walking a Fine Line

2 High-Yield Dividend Stocks to Buy for Passive Income

Pfizer Stock Before Q1 Earnings Release: To Buy or Not to Buy?

What's Next for Pfizer After the Company Pulls Its Weight Loss Drug?

S&P 500 Sell-Off: 2 Ultra-High-Yield Dividend Stocks That Make for No-Brainer Buys

Novo Nordisk Pops After Leapfrogging Eli Lilly With An Obesity Pill

Jim Cramer Warns on Pfizer (PFE): “That 7.7% Yield Is Not a Sign of Strength – It’s a Sign of Weakness”

Performance Overview